RPG Life Sciences cash flow

Latest FY26
Cash from operations
₹56.5cr−27.4% on FY25
Capital spending
₹65.4crNo figure a year before
Free cash flow
−₹8.9cr₹77.9 cr in FY25
Cash from financing
−₹20.6cr−₹27.1 cr in FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Adjustments to reconcile profit — non-cash items
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
—21.521.417.115.5
—9.2———
—0.9———
—−9.7———
—−0.6———
—−2.4———
—−36.1———
—−0.0———
Changes in working capital
—−30.96.2—−12.1
—−29.6−35.8−14.3−5.4
—4.0———
—0.0———
—−20.0———
—17.69.56.319.3
—1.5———
—−0.8———
—15.0———
Cash from operating activities
148154———
—−60.5———
—93.7131124116
—37.252.829.325.2
—56.577.994.490.8
Cash from investing activities
—65.4———
—0.0109——
—9.73.2—2.7
—142———
—85.8−41.8−79.2−106
Cash from financing activities
—20.0———
—0.0——0.3
—0.9—0.5—
—39.7—19.9—
—−20.6−27.1−20.3−17.1
—122———
—122——−32.1
——28.719.724.8
Reference items
156147———
20.5%20.8%———
−8.9−8.977.994.490.8
−₹5.36−₹5.36₹47.08₹57.06₹54.92
—0.49×———
—37.252.829.325.2
—0.9—0.5—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

RPGLIFE₹2,844.00

RPG Life Sciences Limited

· Pharma & Health
₹ CrorePeersGUFICBIOGUJTHEMUNICHEMLABORCHPHARMASMSPHARMAFDCIOLCPINDSWFTLABMcap ₹4,703 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation15.517.121.421.5—
+ Impairment Loss / (Reversal)———9.2—
+ Finance Costs———0.9—
+ Interest Income———-9.7—
+ Unrealised FX (Gain) / Loss———-0.6—
+ Other Non-cash Items———-2.4—
+ Other — Cash Effects are Investing / Financing———-36.1—
+ Other Reconciling Items———-0.0—
Changes in Working Capital
+ Inventories-12.1—6.2-30.9—
+ Trade Receivables — Current-5.4-14.3-35.8-29.6—
+ Other Financial Assets — Current———4.0—
+ Other Financial Assets — Non-current———0.0—
+ Other Current Assets———-20.0—
+ Trade Payables — Current19.36.39.517.6—
+ Other Financial Liabilities — Current———1.5—
+ Other Current Liabilities———-0.8—
+ Provisions — Non-current———15.0—
Cash from Operating Activities
Profit Before Tax (per I/S)———154.2147.8
+ Total Adjustments (incl. Working Capital)———-60.5—
Cash from Operations (pre-tax)116.1123.7130.693.7—
+ Income Taxes Paid25.229.352.837.2—
Cash from Operating Activities90.894.477.956.5—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)———65.4—
+ Disp of Fixed Assets——109.50.0—
+ Interest Received — Investing2.7—3.29.7—
+ Other Inflows / (Outflows) — Investing———141.5—
Cash from Investing Activities-105.8-79.2-41.885.8—
Cash from Financing Activities
+ Proceeds from Borrowings———20.0—
+ Repayment of Borrowings0.3——0.0—
+ Interest Paid—0.5—0.9—
+ Dividends Paid—19.9—39.7—
Cash from Financing Activities-17.1-20.3-27.1-20.6—
Net Changes in Cash (pre-FX)———121.8—
Net Changes in Cash-32.1——121.8—
Closing Cash24.819.728.7——
Reference Items
EBITDA———147.1156.3
EBITDA Margin %———20.7920.45
Free Cash Flow (CFO − Capex)90.894.477.9-8.9-8.9
Free Cash Flow per Basic Share54.9257.0647.08-5.36-5.36
Cash Flow to Net Income———0.49—
Cash Paid for Taxes25.229.352.837.2—
Cash Paid for Interest—0.5—0.9—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.